Jim Cramer Just Discussed These 13 Stocks

5. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders In Q3 2024: 81

Johnson & Johnson (NYSE:JNJ) is a mega drug manufacturer that is one of the largest of its kind in the world. The firm is currently facing quite a bit of long-term headwinds from its talcum powder lawsuit which is estimated to cost it more than a billion dollars. Johnson & Johnson (NYSE:JNJ)’s diversified business allows it to run a steady ship despite a billion-dollar lawsuit. This was evident in the firm’s third-quarter earnings which saw it beat analyst revenue estimates of $22.2 billion by posting $22.5 billion. Johnson & Johnson (NYSE:JNJ)’s Medical Technology business is powering the firm these days. Its recent fight with Cigna, as highlighted in a WSJ report, also falls in tune with Cramer’s comments we mentioned in the introduction. That wasn’t all he had to say about Johnson & Johnson (NYSE:JNJ) though:

“Look, all the drug companies. Look at Johnson & Johnson. Triple A balance sheet, obviously has the talc litigation, that’s a problem. Has a problem with IRA. But this is a great, great company, and if you get that chart up, I think you’re going to say, wait a second, holy cow, I mean that’s a very very good company.”